Astex Announces Exclusive Research Collaboration and License Agreement with Genentech for Breast Cancer Therapy Program
Michelle Jones, president of Astex Pharmaceuticals, said, “Working together with colleagues from Newcastle University, Astex’s fragment-based drug discovery expertise has led to the discovery of a novel and innovative approach to selectively inhibit this key oncology target for breast cancer therapy. Genentech’s focus on embracing innovation, its expertise in oncology and its longstanding dedication to innovation for breast cancer patients makes Genentech an excellent partner for this collaboration. We are delighted to be working together in this important drug discovery alliance with the aim to build on our progress and accelerate compounds into development in a rapidly emerging area of need which, as yet, remains unmet.”
Share:
More News
“The positive outcome of our pre-IND interactions with the FDA reinforces the development pathway for MaaT034 and supports its continued advancement toward the clinic. It also represents an important step in MaaT Pharma’s expansion into immuno-oncology, highlighting the broader potential of our first in class co-cultivated microbiome donor-independent platform across
“Patients with metastatic RAS G12D non-squamous NSCLC, occurring in approximately 4% of cases, represent an underserved population, with no approved targeted treatment options. Initial clinical data evaluating zoldonrasib in combination with standard of care pembrolizumab and platinum doublet chemotherapy in patients with previously untreated metastatic RAS G12D non-squamous NSCLC showed
“At Georgiamune, we are focused on uncovering novel mechanisms that control immune-cell function and translating that biology into first-in-class medicines across autoimmune disease and oncology,” said Samir N. Khleif, M.D., Founder and Chief Executive Officer of Georgiamune. “GIM-621 is one of multiple programs to emerge from that work, alongside three
“Our team’s outstanding execution has enabled us to rapidly advance three programs into the clinic in 2026 and make significant progress in developing next-generation IO, ADC and combination therapies. Together with our partner, Kelun-Biotech, we have achieved seven IND clearances to date, and by mid-2027, we expect more than 2,000